Zodak, 10 mg 10 pcs

Zodak is an anti-allergic.

Pharmacodynamics

Cetirizine belongs to the group of competitive histamine antagonists, blocks H₁-histamine receptors, almost has no anticholinergic and antiserotonin action. It has a pronounced anti-allergic effect, prevents the development and facilitates the course of allergic reactions. It has antipruritic and antiexudative effects.

It affects the early stage of allergic reactions and also reduces migration of inflammatory cells; it inhibits the release of mediators involved in late allergic reactions. Reduces capillary permeability, prevents the development of tissue edema, relieves smooth muscle spasm. It eliminates the skin reaction to the introduction of histamine specific allergens, as well as to cooling (with cold urticaria). In therapeutic doses there is practically no sedative effect. Tolerance does not develop during a course of treatment.

The action of the drug starts within 20 minutes (in 50% of patients), after 1 hour (in 95% of patients) and lasts for 24 hours.

Pharmacokinetics

Intake. After oral administration, cetirizine is quickly and well absorbed from the gastrointestinal tract. T_max is approximately 30-60 min.

Eating has no significant effect on the absorption value, but in this case the absorption rate is slightly reduced.

Distribution. Cetirizine binds to blood plasma proteins by approximately 93%. V_d value is low (0.5 l/kg), the drug does not penetrate inside the cell. The drug does not penetrate through the HEB. It penetrates into breast milk.

Metabolism. Cetirizine is weakly metabolized in the liver to form an inactive metabolite. No accumulation of the drug is observed with 10-day use at a dose of 10 mg.

Elimation. About 70% is through the kidneys, mostly unchanged.

The value of systemic clearance is about 54 ml/min.

After a single single single dose, the T_1/2 value is about 10 hours. In children aged 2 to 12 years, the T_1/2 value is reduced to 5-6 h. Hemodialysis is ineffective.

Pharmacokinetics in special groups of patients

Patients with impaired renal function. In patients with impaired renal function (creatinine Cl below 11-31 ml/min) and in patients on hemodialysis (creatinine Cl less than 7 ml/min), the T_1/2 value is increased 3-fold and Cl is decreased by 70%.

Patients in the elderly and patients with chronic diseases. In the background of chronic diseases and in elderly patients, there is a 50% increase in T_1/2 and a 40% decrease in Cl

Advanced for film-coated tablets

Patients with chronic liver disease (hepatocellular, cholestatic and biliary cirrhosis). Patients with cirrhosis have a 50% increase in T_1/2 and a 40% decrease in total clearance (dosing regimen adjustment is only required with concomitant decreased glomerular filtration rate).

Indications

Active ingredient

Composition

1 tablet contains 10 mg cetirizine dihydrochloride;

excipients:

Lactose monohydrate,

Corn starch,

povidone, magnesium stearate,

hydroxypropyl methylcellulose,

macrogol,

Talc,

Titanium dioxide,

Dimethicone emulsion.

How to take, the dosage

Zodak is administered orally, regardless of meals. Dissolve the drops in water before taking. Coated tablets should be swallowed whole with a small amount of water.

Adults and children over 12 years of age – 10 mg cetirizine (1 tablet, 20 drops or 2 scoops of syrup).

Children from 6 to 12 years – 10 mg cetirizine (1 tablet, 20 drops or 2 scoops of syrup) once daily or 5 mg cetirizine (10 drops or 1 scoop of syrup) two times daily, morning and evening.

Children from 2 to 6 years – 5 mg cetirizine (1/2 tablet, 10 drops or 1 scoop of syrup) once a day or 2.5 mg cetirizine (5 drops or 1/2 scoop of syrup) 2 times a day, morning and evening.

In children 1 to 2 years old, 2.5 mg (5 drops) 2 times a day.

Interaction

Co-administration with theophylline (400 mg/day) decreases total clearance of cetirizine (the kinetics of theophylline does not change).

Special Instructions

Patients with impaired hepatic and/or renal function and the elderly should consult a physician before taking the drug (see “Pharmacokinetics”, “Dosage and administration”).

Impact on the ability to drive a car or perform work requiring an increased rate of physical and mental reactions. During treatment, it is necessary to refrain from engaging in potentially hazardous activities requiring increased concentration and speed of psychomotor reactions.

The concomitant use of medications that depress the central nervous system and alcohol is not recommended.

Contraindications

With caution: moderate to severe chronic renal insufficiency (dosage regimen adjustment is required), advanced age (decreased glomerular filtration possible).

Side effects

Digestive system disorders: dry mouth, dyspepsia.

CNS disorders: headache, drowsiness, fatigue, dizziness, agitation, migraine.

Allergic reactions: skin rash, angioedema, urticaria, itching.

Overdose

Symptoms: drowsiness, lethargy, weakness, fatigue, headache, tachycardia, increased irritability, delayed urination, dry mouth, constipation (most often when taking 50 mg cetirizine daily).

Treatment: symptomatic therapy. Gastric lavage, prescription of activated charcoal. No specific antidote has been identified. Hemodialysis is ineffective.

Similarities